Voyager Therapeutics Inc
VYGR3.220USD
+0.260+8.78%
交易中 （美东）报价延迟15分钟
177.77M总市值
亏损市盈率 TTM
关于 Voyager Therapeutics Inc 公司
Voyager Therapeutics, Inc. 是一家专注于推进神经遗传药物的生物技术公司。该公司的研发线包括针对阿尔茨海默病、肌萎缩侧索硬化症 (ALS)、帕金森病和多种其他中枢神经系统疾病的项目。该公司的许多项目都源自其 TRACER AAV 衣壳发现平台，该平台用于生成新型衣壳并识别相关受体，从而有可能使基因药物在静脉注射后实现高脑渗透。该公司的研发线项目均处于临床前开发阶段，包括抗 Tau 抗体 (VY-TAU01)、SOD1 沉默基因治疗项目、Tau 沉默基因治疗项目、矢量化抗淀粉样蛋白抗体早期研究项目、弗里德赖希共济失调项目：VY-FXN01、GBA1 基因置换项目、HD 项目等。VY-TAU01 用于治疗阿尔茨海默病。 SOD1沉默基因治疗计划用于治疗 ALS。
公司简介
公司代码VYGR
公司名称Voyager Therapeutics Inc
上市日期Nov 11, 2015
CEODr. Alfred W. Sandrock, M.D., Ph.D.
员工数量172
证券类型Ordinary Share
年结日Nov 11
公司地址75 Hayden Avenue
城市LEXINGTON
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02421
电话18572595340
网址https://www.voyagertherapeutics.com/
公司代码VYGR
上市日期Nov 11, 2015
CEODr. Alfred W. Sandrock, M.D., Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Alfred W. Sandrock, M.D., Ph.D.
Dr. Alfred W. Sandrock, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
134.26K
-25.20%
Ms. Robin Swartz
Ms. Robin Swartz
Chief Operating Officer, Chief Business Officer
Chief Operating Officer, Chief Business Officer
84.49K
+250.80%
Dr. Toby Ferguson, M.D., Ph.D.
Dr. Toby Ferguson, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.91K
-85.17%
Dr. Glenn F. Pierce, M.D., Ph.D.
Dr. Glenn F. Pierce, M.D., Ph.D.
Independent Director
Independent Director
21.79K
--
Dr. Jude Onyia, Ph.D.
Dr. Jude Onyia, Ph.D.
Director
Director
2.91K
--
Dr. George A. Scangos, Ph.D.
Dr. George A. Scangos, Ph.D.
Independent Director
Independent Director
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Todd Carter, Ph.D.
Dr. Todd Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. James Arthur (Jim) Geraghty, J.D.
Mr. James Arthur (Jim) Geraghty, J.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Alfred W. Sandrock, M.D., Ph.D.
Dr. Alfred W. Sandrock, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
134.26K
-25.20%
Ms. Robin Swartz
Ms. Robin Swartz
Chief Operating Officer, Chief Business Officer
Chief Operating Officer, Chief Business Officer
84.49K
+250.80%
Dr. Toby Ferguson, M.D., Ph.D.
Dr. Toby Ferguson, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.91K
-85.17%
Dr. Glenn F. Pierce, M.D., Ph.D.
Dr. Glenn F. Pierce, M.D., Ph.D.
Independent Director
Independent Director
21.79K
--
Dr. Jude Onyia, Ph.D.
Dr. Jude Onyia, Ph.D.
Director
Director
2.91K
--
Dr. George A. Scangos, Ph.D.
Dr. George A. Scangos, Ph.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Neurocrine Biosciences Inc
15.50%
Armistice Capital LLC
9.82%
EcoR1 Capital, LLC
7.08%
BlackRock Institutional Trust Company, N.A.
6.58%
The Vanguard Group, Inc.
5.80%
Other
55.22%
持股股东
持股股东
占比
Neurocrine Biosciences Inc
15.50%
Armistice Capital LLC
9.82%
EcoR1 Capital, LLC
7.08%
BlackRock Institutional Trust Company, N.A.
6.58%
The Vanguard Group, Inc.
5.80%
Other
55.22%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
23.35%
Investment Advisor
20.26%
Hedge Fund
16.83%
Corporation
15.50%
Research Firm
2.35%
Individual Investor
1.32%
Bank and Trust
0.57%
Pension Fund
0.50%
Venture Capital
0.03%
Other
19.30%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
301
44.67M
80.73%
-3.34M
2025Q1
320
44.96M
81.54%
-6.59M
2024Q4
316
44.59M
81.64%
-6.62M
2024Q3
302
45.03M
82.56%
-8.55M
2024Q2
298
47.92M
88.05%
-2.79M
2024Q1
277
45.43M
90.18%
+7.85M
2023Q4
257
36.58M
85.81%
-1.09M
2023Q3
248
36.63M
86.15%
-1.09M
2023Q2
242
36.26M
85.84%
+5.02M
2023Q1
252
33.40M
79.73%
+1.16M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Neurocrine Biosciences Inc
8.58M
15.5%
--
--
Apr 07, 2025
Armistice Capital LLC
5.44M
9.82%
+40.00K
+0.74%
Mar 31, 2025
EcoR1 Capital, LLC
3.92M
7.08%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.64M
6.58%
+9.42K
+0.26%
Mar 31, 2025
The Vanguard Group, Inc.
3.21M
5.8%
-4.36K
-0.14%
Mar 31, 2025
Farallon Capital Management, L.L.C.
2.57M
4.65%
--
--
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.50M
2.7%
+115.67K
+8.38%
Mar 31, 2025
BlackRock Financial Management, Inc.
1.43M
2.58%
+56.45K
+4.12%
Mar 31, 2025
Vestal Point Capital, LP
1.25M
2.26%
+19.42K
+1.58%
Mar 31, 2025
Erste Asset Management GmbH
1.12M
2.02%
+58.41K
+5.52%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Invesco NASDAQ Future Gen 200 ETF
0.51%
Tema Neuroscience and Mental Health ETF
0.42%
iShares Neuroscience and Healthcare ETF
0.34%
iShares Health Innovation Active ETF
0.06%
WisdomTree US SmallCap Fund
0.03%
WisdomTree US SmallCap Quality Growth Fund
0.03%
iShares Micro-Cap ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
查看更多
Invesco NASDAQ Future Gen 200 ETF
占比0.51%
Tema Neuroscience and Mental Health ETF
占比0.42%
iShares Neuroscience and Healthcare ETF
占比0.34%
iShares Health Innovation Active ETF
占比0.06%
WisdomTree US SmallCap Fund
占比0.03%
WisdomTree US SmallCap Quality Growth Fund
占比0.03%
iShares Micro-Cap ETF
占比0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0.02%
Invesco Nasdaq Biotechnology ETF
占比0.02%
ProShares Ultra Nasdaq Biotechnology
占比0.02%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
